PRF Technologies (PRFX) reports PRF-110 pain-relief data comparable to ZYNRELEF
Filing Impact
Filing Sentiment
Form Type
6-K
Rhea-AI Filing Summary
PRF Technologies Ltd. filed a Form 6-K to share preclinical data for its lead pain-management candidate, PRF-110. In a head-to-head study in domestic pigs, a single wound-bed dose of PRF-110 showed sustained analgesic activity over 72 hours that was comparable to ZYNRELEF, an approved extended-release local anesthetic benchmark.
PRF-110 is an oil-based, viscous extended-release formulation of ropivacaine, designed for direct administration into the surgical wound to provide prolonged local pain relief and potentially reduce post-surgical opioid use. The formulation is ropivacaine-only and NSAID-free, leveraging a long-acting anesthetic that has shown lower cardiac toxicity than bupivacaine in non-clinical studies. The company views these results as supportive as it plans further development and regulatory strategy for PRF-110.
Positive
- None.
Negative
- None.
Insights
Positive preclinical pain data, but still early and non-clinical.
The report highlights that PRF-110, a ropivacaine-based extended-release formulation, achieved 72-hour analgesic activity in pigs comparable to approved product ZYNRELEF. This supports the scientific rationale for a non-opioid, NSAID-free local anesthetic designed for single-dose surgical wound application.
The data come from a validated pig incisional pain model using von Frey methodology, which is standard for assessing post-operative pain therapies. However, these are preclinical findings and not human clinical outcomes, so regulatory and commercial relevance will depend on future trials.
The company explicitly frames the results as supportive for shaping PRF-110’s development and regulatory strategy, including study design and formulation positioning. Subsequent clinical studies and regulatory interactions, when disclosed in future filings, will be key to understanding potential timelines and risk.
Key Figures
Analgesic duration: 72 hours
Comparator drug: ZYNRELEF
Anesthetic agent: Ropivacaine-only
3 metrics
Analgesic duration
72 hours
Post-surgical evaluation period in preclinical pig study
Comparator drug
ZYNRELEF
Approved extended-release product used as benchmark in study
Anesthetic agent
Ropivacaine-only
NSAID-free extended-release formulation in PRF-110
Key Terms
extended-release formulation, incisional pain model, von Frey methodology, forward-looking statements, +1 more
5 terms
extended-release formulation medical
"a proprietary, oil-based, viscous, clear extended-release formulation of ropivacaine"
An extended-release formulation is a medicine designed to release its active ingredient slowly over an extended period instead of all at once, like a timed sprinkler that waters a lawn gradually rather than flooding it. For investors, it matters because this design can improve patient convenience and adherence, support premium pricing, extend commercial life versus immediate-release versions, and create different regulatory and competitive dynamics that affect sales and profitability.
incisional pain model medical
"The preclinical study was conducted in a validated pig incisional pain model"
An incisional pain model is a controlled experimental setup that mimics the pain people feel after a surgical cut so researchers can measure how well pain treatments work. Think of it as a test track where new pain drugs or devices are tried under predictable conditions to see if they reduce pain and speed recovery; for investors, positive results in these models can de-risk drug development and indicate potential clinical value.
von Frey methodology medical
"conducted in a validated pig incisional pain model, with von Frey methodology"
A laboratory test that measures how sensitive skin or tissue is to light touch by pressing a series of calibrated filaments of increasing stiffness until the subject withdraws or reports sensation. Investors should care because this common pain-sensitivity test is used in preclinical and clinical trials to show whether a drug or device reduces touch-evoked pain; consistent, well-controlled results can influence efficacy claims, regulatory review, and market prospects.
forward-looking statements regulatory
"This press release contains forward-looking statements about PRF’s expectations, beliefs and intentions"
Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.
post-operative analgesia medical
"to provide localized and extended post-operative analgesia"
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
For the month of May 2026
Commission File Number: 001-39481
PRF Technologies Ltd.
(Translation of registrant’s name into English)
65 Yigal Alon St., Tel Aviv 6744316
Israel
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
The first three paragraphs of the press release attached hereto as Exhibit 99.1 are incorporated by reference into the registrant’s Registration Statements on Form S-8 (Registration No. 333-257968 and 333-265902) and the registrant’s Registration
Statements on Form F-3 (Registration No. 333-282264, 333-254982,
333-276485, 333-277594, 333-283655 and 333-286941), to be a part thereof from the
date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.
On May 26, 2026, PRF Technologies Ltd. issued a press release entitled “PRF Technologies Announces PRF-110 Demonstrated Sustained 72-Hour Analgesic Activity Comparable to Approved, Commercially
Available Benchmark in Head-to-Head Preclinical Study”. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.
Exhibit Index
|
Exhibit No.
|
Description
|
|
|
|
|
|
|
99.1
|
Press Release dated May 26, 2026.
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
Date: May 26, 2026
|
PRF TECHNOLOGIES LTD.
|
|
|
|
|
|
|
|
By:
|
/s/ Ehud Geller
|
|
|
|
Ehud Geller
Executive Chairman of the Board
|
Exhibit 99.1
PRF Technologies Announces PRF-110 Demonstrated Sustained 72-Hour
Analgesic Activity Comparable to Approved, Commercially Available
Benchmark in Head-to-Head Preclinical Study
Ropivacaine-only, NSAID-free formulation leverages a long-acting local anesthetic with a
favorable safety profile
Tel Aviv – May 26, 2026 — PRF Technologies Ltd. (Nasdaq: PRFX) (“PRF” or the “Company”), a clinical-stage specialty
pharmaceutical company focused on reformulating established therapeutics for post-operative pain management, today announced positive results from a preclinical study in domestic pigs directly comparing its lead product candidate, PRF-110, to
ZYNRELEF® (bupivacaine and meloxicam extended-release solution), an approved extended-release product used as a benchmark in the study.
PRF-110 is a proprietary, oil-based, viscous, clear extended-release formulation of ropivacaine designed to be deposited directly into the surgical wound bed
prior to closure. The product candidate is being developed to provide prolonged local analgesia following surgery through a single administration at the surgical site. Such product is designed to reduce the use of opiates for post-surgical pain.
In the head-to-head preclinical study, PRF-110 demonstrated sustained analgesic activity comparable to ZYNRELEF across the 72-hour post-surgical evaluation
period. Importantly, PRF-110 achieved this activity with a ropivacaine-only, NSAID-free formulation. Ropivacaine is a well-characterized long-acting local anesthetic that has demonstrated lower cardiac toxicity than bupivacaine in non-clinical
pharmacology studies.
“For physicians, the key question is whether a new non-opioid therapy can provide sustained pain relief while offering a differentiated clinical profile,”
said Dr. Ehud Geller, Executive Chairman of PRF Technologies. “PRF-110 demonstrated sustained analgesic activity comparable to an approved benchmark over 72 hours in this head-to-head preclinical study. Importantly, PRF-110 achieved this activity
with a ropivacaine-only, NSAID-free formulation. Given ropivacaine’s demonstrated lower cardiac toxicity than bupivacaine in non-clinical pharmacology studies, we believe PRF-110’s formulation profile may represent an important potential advantage as
we evaluate the next steps in development.”
Dr. Geller continued, “Post-operative pain remains a significant clinical and public health challenge, particularly as physicians and healthcare systems
continue to seek effective ways to reduce reliance on opioids. Once successfully developed and approved, PRF-110 could provide physicians with an additional non-opioid option that combines sustained local analgesia, direct wound-bed administration
and a differentiated formulation profile.”
Study Design
The preclinical study was conducted in a validated pig incisional pain model, with von Frey methodology, used extensively to evaluate post-operative analgesic
therapies. Animals were randomized to receive a single administration of either PRF-110 or ZYNRELEF into the surgical wound bed prior to closure. Pain-related endpoints were assessed at multiple timepoints over a 72-hour post-operative period.
Analgesic activity was evaluated using standard measures of incisional pain in pigs, including behavioral and functional parameters, as well as
stimulus-evoked responses. The active treatment arms were assessed for magnitude and duration of analgesic effect across early and late post-operative time windows.
Key Results
| • |
PRF-110 and ZYNRELEF each produced clear reductions in pain-related measures, confirming post-operative analgesic activity for both extended-release local analgesic formulations.
|
| • |
Across the overall 72-hour assessment period, PRF-110’s analgesic effect was comparable to ZYNRELEF on the primary efficacy endpoints evaluated in this head-to-head preclinical setting.
|
| • |
At later post-operative timepoints, PRF-110 maintained analgesic efficacy comparable to ZYNRELEF, supporting the sustained-release characteristics of PRF-110 following a single administration.
|
| • |
PRF-110’s safety and local tolerability profile in pigs was consistent with prior preclinical experience, with no unexpected findings observed at the doses tested.
|
PRF believes the findings provide useful supportive data as the Company evaluates the next steps for PRF-110’s development and regulatory strategy. The
Company believes the head-to-head comparison with an approved benchmark may help inform future development planning for PRF-110, including study design, formulation positioning and potential regulatory engagement.
ZYNRELEF is used in this release solely as a comparator product. ZYNRELEF is a registered trademark of Heron Therapeutics, Inc. PRF Technologies is not
affiliated with Heron Therapeutics, Inc., and this announcement is not sponsored, endorsed or authorized by Heron Therapeutics, Inc.
About PRF-110
PRF-110 is a proprietary, oil-based, viscous, clear extended-release solution based on the local anesthetic ropivacaine and is being developed for the
post-operative pain relief market. PRF-110 is designed to be deposited directly into the surgical wound bed prior to closure to provide localized and extended post-operative analgesia. The formulation is designed to remain in place at the surgical
site, spread over and adhere to the wound surface, resist rapid clearance, and provide sustained local release of ropivacaine. PRF-110 is being developed to provide prolonged post-operative pain relief following a single administration, with the goal
of reducing the need for repeated dosing and potentially reducing reliance on opioids after surgery.
About PRF Technologies
PRF Technologies (Nasdaq: PRFX) is a company focused on the reformulation of established therapeutics, and a developer of AI-driven energy optimization technologies through its DeepSolar platform.
The Company’s pharmaceutical programs leverage a proprietary extended-release drug-delivery system intended to provide prolonged post-surgical pain relief while minimizing the need for repeated dosing and reducing reliance on opioids. Through
DeepSolar, PRF also delivers advanced software solutions that enable both consumers and enterprises to monitor, forecast, and optimize energy consumption - particularly in solar-integrated environments. This dual business model reflects PRF’s
strategic commitment to applying precision technology across high-impact sectors including healthcare and sustainable energy. For more information, please visit www.prf-tech.com.
Notice Regarding Forward-Looking Statements
This press release contains forward-looking statements about PRF’s expectations, beliefs and intentions including with respect to statements related to the prospects for PRF-110
and its development plan. Forward-looking statements can be identified by the use of forward-looking words such as “believe”, “expect”, “intend”, “plan”, “may”, “should”, “could”, “might”, “seek”, “target”, “will”, “project”, “forecast”, “continue”
or “anticipate” or their negatives or variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical matters. These forward-looking statements are based on assumptions and assessments
made in light of management’s experience and perception of historical trends, current conditions, expected future developments and other factors believed to be appropriate. Forward-looking statements in this press release are made as of the date of
this press release, and we undertake no duty to update or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks and
uncertainties, many of which are outside of our control. Many factors could cause our actual activities or results to differ materially from the activities and results anticipated in forward- looking statements, including, but not limited to, the
following: our ability to continue as a going concern, our history of significant losses, our need to raise additional capital and our ability to obtain additional capital on acceptable terms, or at all; our dependence on the success of our initial
product candidate, PRF-110 OcuRing™-K, LayerBio Inc.’s lead product candidate, and the commercialization of the DeepSolar solution; the outcomes of preclinical studies, clinical trials and other research regarding PRF-110, OcuRing™-K and future
product candidates; our limited experience managing clinical trials; our ability to retain key personnel and recruit additional employees; our reliance on third parties for the conduct of clinical trials, product manufacturing and development; the
impact of competition and new technologies; our ability to comply with regulatory requirements relating to the development and marketing of our product candidates; our ability to establish and maintain strategic partnerships and other corporate
collaborations; the implementation of our business model and strategic plans for our business and product candidates; the scope of protection we are able to establish and maintain for intellectual property rights and our ability to operate our
business without infringing the intellectual property rights of others; the overall global economic environment; our ability to develop an active trading market for our ordinary shares and whether the market price of our ordinary shares is volatile;
our ability to maintain our listing on the Nasdaq Capital Market; and statements as to the impact of the political and security situation in Israel on our business. More detailed information about the risks and uncertainties affecting us is contained
under the heading “Risk Factors” included in the Company’s most recent Annual Report on Form 20-F and in other filings that we have made and may make with the Securities and Exchange Commission in the future.
Contact:
Crescendo Communications, LLC
Tel: 212-671-1021
Email: prfx@crescendo-ir.com
Dr. Ehud Geller, Chairman
PRF Technologies Ltd.
Tel: +972-54-4236711
Email: egeller@medicavp.com
FAQ
What did PRF Technologies (PRFX) report about PRF-110 on this Form 6-K?
PRF Technologies reported positive preclinical pig data for PRF-110, showing 72-hour analgesic activity comparable to approved benchmark ZYNRELEF. The results support continued development of this non-opioid, extended-release local anesthetic for post-operative pain management.
How did PRF-110 perform versus ZYNRELEF in the preclinical study for PRFX?
In a head-to-head preclinical study in domestic pigs, PRF-110 demonstrated sustained analgesic activity over 72 hours comparable to ZYNRELEF. Both were administered once into the surgical wound bed, and pain-related endpoints were assessed over the 72-hour post-operative period.
What is unique about PRF Technologies’ PRF-110 formulation?
PRF-110 is a proprietary, oil-based, viscous extended-release solution containing only ropivacaine and no NSAID. It is designed for direct wound-bed administration, to stay in place, spread over the wound surface, and release ropivacaine locally over time to reduce post-surgical opioid use.
What stage of development is PRF-110 according to PRF Technologies’ 6-K?
PRF Technologies describes itself as a clinical-stage specialty pharmaceutical company and reports preclinical head-to-head data for PRF-110. The company states these findings provide supportive information as it evaluates next steps in PRF-110’s development and regulatory strategy.
What businesses does PRF Technologies (PRFX) operate beyond PRF-110?
PRF Technologies develops extended-release pharmaceutical products for post-surgical pain and also offers AI-driven energy optimization through its DeepSolar platform. DeepSolar provides software that helps consumers and enterprises monitor, forecast, and optimize energy use, particularly in solar-integrated environments.